MDNAF News and Press, Mandatum Pankki Oyj From 07/01/20

Medicenna Therapeutics Corp. [TSX:MDNA] ( OTCQB:MDNAF ) is a Toronto-based clinical-stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines. Superkines can be engineered as short or long-acting therapeutics or fused with cell-killing protei...

TORONTO and HOUSTON , June 11, 2020 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA) (OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, ...

The following slide deck was published by Medicenna Therapeutics Corp. in conjunction with this Read more ...

The following slide deck was published by Medicenna Therapeutics Corp. in conjunction with this Read more ...

Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020 Canada NewsWire TORONTO, May 29, 2020 -MDNA11, a long acting IL-2 super-agonist shows potent and durable tumor control with strong memory response in tumor models- -Up to 10-fold expansion of cancer-killing...

Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020 Canada NewsWire TORONTO and HOUSTON, May 29, 2020 -Tumor control achieved in 76% of evaluable subjects irrespective of IL4R expression resulting in mOS, mPFS and PFS-12 of 15.0 months, 4.6 mon...

Medicenna Announces March 31, 2020 Year-End Results Canada NewsWire TORONTO and HOUSTON, May 15, 2020 -     End of Phase 2 meeting package for MDNA55 to be submitted in Q2 2020- -     IND submission for IL-2 Superkine Platform calen...

Data from MDNA55 Clinical Program and IL-2 Superkine Program TORONTO and HOUSTON , May 4, 2020 /PRNewswire/ - Medicenna Therapeutics Corp.  (" Medicenna " or " the Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it wi...

Medicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public Offering Canada NewsWire TORONTO and HOUSTON, April 15, 2020 /NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ Funds to be Dedicate...

Medicenna Therapeutics Corp. [TSX:MDNA] ( OTCQB:MDNAF ) is a Toronto based clinical-stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines. Superkines can be engineered as short or long-acting therapeutics or fused with cell-killing protei...